Page 97 - GHES-1-1

Global Health Econ Sustain Impact of new drug indications in Brazil

Sleijfer`, S., & Verweij, J. (2016). Health policy: Affordability The Lowdown. (2021). Billions are Spent by the NHS on Drugs
of drugs used in oncology health care. Natural Reviews, Every Year, but how does it Work? The Lowdown. Available
Clinical Oncology, 13(6):331-332. from: https://lowdownnhs.info/drugs/billions-are-spent-
by-the-nhs-on-drugs-every-year-but-how-does-it-work
https://doi.org/10.1038/nrclinonc.2016.77
[Last accessed on 2023 Apr 25].
Tartari, F., Santoni, M., Burattini, L., Mazzanti, P., Onofri, A., &
Berardi, R. (2016). Economic sustainability of anti-PD-1 Viscusi, W.K., Harrington, J.E., & Vernon, J.M. (2005). Economics of
th
agents nivolumab and pembrolizumab in cancer patients: Regulation and Antitrust. 4 ed. Cambridge, Mass: MIT Press.
Recent insights and future challenges. Cancer Treatment Yu, P.P. (2016). Challenges in measuring cost and value in
Reviews, 48:20-24. oncology: Making it personal. Value in Health, 19(5):520-524.
https://doi.org/10.1016/j.ctrv.2016.06.002 https://doi.org/10.1016/j.jval.2016.04.017

Volume 1 Issue 1 (2023) 10 https://doi.org/10.36922/ghes.0994